好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Accuracy of Seizure Burden Monitoring and Detection of Status Epilepticus with the Clarity AI Algorithm
Epilepsy/Clinical Neurophysiology (EEG)
P2 - Poster Session 2 (11:45 AM-12:45 PM)
11-001

To evaluate the performance of Clarityv8 artificial intelligence (AI) algorithm (Ceribell, Inc.) in detecting status epilepticus (SE) and seizures in a large retrospective adult dataset. 

Point-of-care electroencephalography (POC EEG) systems enhanced with AI algorithms may bridge gaps in timely EEG access and seizure triage.

We analyzed 1340 adult POC EEGs acquired with the Ceribell EEG system.  Two or more experts marked epochs of seizure and other pathological activity; from these an EEG label was assigned per file per reviewer.  EEGs were labeled as SE if the seizures’ cumulative duration over any 5-min window was ≥4.5min or if seizures were present for ≥20% of any 1-hour window.  The Clarityv8 AI maximum estimated seizure burden (SzB) was extracted per file.  Detection of SE was evaluated at SzB ≥50% and ≥90%, including if any 1-hour window had seizures for ≥12-min. We also evaluated detection of seizures/SE at ≥1% and ≥10% SzB.

Of 1340 EEGs, expert consensus identified 25 EEGs meeting criteria for SE and 51 with non-SE seizures. For SE detection, Clarityv8 AI at SzB ≥90% correctly identified 24 cases for a 96.0% sensitivity, with 94.8% specificity and 99.9% negative predictive value (NPV). For SzB ≥50%, the sensitivity, specificity, and NPV were 96%, 93.3%, and 99.9%, respectively.  In the missed SE case, Clarity’s SzB was 10%. For seizures/SE detection, with SzB ≥10%, the sensitivity, specificity, and NPV were 88.2%, 86.1%, and 99.2% respectively. And with SzB ≥1%, the sensitivity was 96.1% with a specificity of 74.0% and a NPV of 99.7%.

In a large real-world dataset, Clarityv8 AI demonstrated high performance for SE and seizure detection. Its high NPV offers a clinically useful tool for immediate rule out of seizures and SE during neuroemergencies, underscoring the value of AI algorithms as flexible tools to triage patients and potentially reducing empiric treatments.

Authors/Disclosures
Josef Parvizi, MD, PhD (Neurology Clinic)
PRESENTER
Dr. Parvizi has received personal compensation in the range of $100,000-$499,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ceribell. Dr. Parvizi has or had stock in Ceribell.Dr. Parvizi has received intellectual property interests from a discovery or technology relating to health care.
Neeti Gupta, MD Dr. Gupta has nothing to disclose.
Michelle Armenta Salas, PhD Dr. Armenta Salas has received personal compensation for serving as an employee of Ceribell, Inc.. Dr. Armenta Salas has stock in Ceribell, Inc..
Suganya Karunakaran (Drexel University School of Biomed Engg) Ms. Karunakaran has received personal compensation for serving as an employee of Ceribell Inc. Ms. Karunakaran has stock in Ceribell Inc. Ms. Karunakaran has received intellectual property interests from a discovery or technology relating to health care.
Tanaya Puranik, MS Ms. Puranik has received personal compensation for serving as an employee of Ceribell. Ms. Puranik has stock in Ceribell. Ms. Puranik has received intellectual property interests from a discovery or technology relating to health care.
Baharan Kamousi, PhD Dr. Kamousi has received personal compensation for serving as an employee of Ceribell. Dr. Kamousi has stock in Ceribell.